Table 1. Patient characteristics (N = 80).
| Group | |||
|---|---|---|---|
| PCI (N = 60) | non-PCI (N = 20) | p value | |
| Age at diagnosis, years | 0.028 | ||
| Median (Range) | 64 (34–82) | 72.5 (56–83) | |
| Gender | 0.168 | ||
| Male | 43 (72) | 11 (55) | |
| Female | 17 (28) | 9 (45) | |
| Performance status | 0.210 | ||
| 0 | 37 (62) | 11 (55) | |
| 1 | 23 (38) | 8 (40) | |
| 2 | 0 (0) | 1 (5) | |
| Smoking history | 0.013 | ||
| Current/Former | 60 (100) | 18 (90) | |
| Never | 0 (0) | 2 (10) | |
| Stage | 0.184 | ||
| IIA | 4 (7) | 1 (5) | |
| IIB | 4 (7) | 5 (25) | |
| IIIA | 29 (48) | 7 (35) | |
| IIIB | 15 (25) | 6 (30) | |
| IIIC | 8 (13) | 1 (5) | |
| Platinum-containing drug | 0.002 | ||
| CDDP | 54 (90) | 12 (60) | |
| CBDCA | 6 (10) | 8 (40) | |
| TRT method | <0.001 | ||
| Concurrent | 58 (97) | 11 (55) | |
| Sequential | 2 (3) | 9 (45) | |
| Response to treatment | 0.133 | ||
| CR | 23 (38) | 4 (20) | |
| PR | 37 (62) | 16 (80) | |
Abbreviation: PCI, prophylactic cranial irradiation; CDDP, cisplatin; CBDCA, carboplatin; CR, complete response; PR, partial response.